Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- 6 December 2016
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 389 (10087), 2430-2442
- https://doi.org/10.1016/s0140-6736(16)32454-0
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Emerging landscape of oncogenic signatures across human cancersNature Genetics, 2013
- Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the OutcomeClinical Breast Cancer, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast CancerThe New England Journal of Medicine, 2012
- Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancerNature Medicine, 2011
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene, 2010
- The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breastEuropean Journal of Cancer, 2009
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004